My annual tradition of @ecancer ESMO highlights video continues! Watch this video for an unbiased commentary on the most important trials and news coming out of #ESMO26. https://t.co/lOllRbpkJt
Men get your #PSA test for #prostatecancer! A new screening guideline update today from @americancancer researchers led by Dr. Robert Smith &
@billdahutmd in @CACancerJournal recommends PSA testing starting at 50 for men at average risk. Read more here: https://t.co/a8Egea7Hol
Can AI help predict breast cancer recurrence risk? 🤔
New research suggests it may have an important role.
In a recent @ecancer interview, Dr. Laura van 't Veer (@LVVPrint) discusses an investigational AI-based digital MammaPrint assay that demonstrated a strong correlation (r = 0.954) between risk scores generated from digital pathology images and those from the established 70-gene MammaPrint assay.
🎥 Learn more: https://t.co/snjsPKbNEH
#BreastCancerResearch #PrecisionOncology #MammaPrint #ESMO26
Do you know that the @ecancer#ESMO26 highlights video are separated by tumor types and are time stamped so that you can just select the tumor type and trials you want to listen to? These are the breast cancer trials, for example. https://t.co/lOllRboMTV
My annual tradition of @ecancer ESMO highlights video continues! Watch this video for an unbiased commentary on the most important trials and news coming out of #ESMO26. https://t.co/lOllRbpkJt
sac-TMT reduced the risk of disease progression or death by 41% and the risk of death by 32% vs chemo in advanced or recurrent endometrial cancer. Watch @BPothuri discuss TroFuse-005 trial👉 https://t.co/SAV2Det6D5 #ESMO26#EndometrialCancer#CancerResearch
Thank you everyone who attended our proffered paper policy session yesterday. Thankful to the scientific session for selecting our abstract for oral. Thank you to the chairs and discussants for creating this fantastic session and for putting our results into context. @myESMO #ESMO26
Pembrolizumab monotherapy improves PFSl and QoL in advanced or recurrent dMMR endometrial cancer. Watch Dr Brian Slomovitz discuss his study👉https://t.co/atwL17htrZ #EndometrialCancer#ESMO26#CancerResearch@GynCancerMD
Interim MOIO trial reveals routine de-escalation of checkpoint inhibitors based solely on initial response is not supported by prospective data. Watch Dr Gwenaëlle Gravis discuss the trial 👉https://t.co/kpeGUw6MfL @paoli_calmettes#ESMO26
Oral abstract #BreastCancer session at #ESMO26: prospective data on ADC sequencing showing very limited activity with the second ADC by only changing the target
@OncoAlert@myESMO
Intismeran autogene + pembrolizumab reduces the risk of recurrence or death by 42% in resected stage IIB–IV melanoma, improving recurrence-free survival vs pembrolizumab alone. Watch @ProfGLongMIA speak to ecancer👉https://t.co/uVv5FBy1MI #ESMO26
AZUR-1 delivers. #ESMO26
Phase 2, single arm. Dostarlimab x 9 cycles (6 months) in untreated stage II/III dMMR/MSI-H rectal cancer, 154 patients.
Cercek's 49-patient NEJM cohort gone global.
No control arm, because randomizing these patients to TNT/TME isn't equitable.
cCR12 (complete response held 12+ months, no further treatment): 68% by investigator. 26% needed additional treatment 10% went to surgery
68% is likely lower than reality since many patients probably just needed more time to radiographically respond. Using PET/Biopsy/ctDNA, especially ctDNA, is incredibly helpful in my practice to identify patients who can avoid TME even if a fibrotic tumor remains as they often do.
FDA already gave accelerated approval (way to steal the ESMO thunder) last week which leads me to my next point.
Obvious new standard of care. You should go to oncology jail if you don't treat MSI-H with IO.
@OncoAlert@TheGutOncLab@Onco_Nexus
Divarasib significantly improved PFS (9.8 vs 5.7 m) and OS (12 vs 17.7) vs control (soto or ada) with a manageable safety profile (GI toxicity) in previously treated advanced/metastatic KRAS G12C-mutated NSCLC. @myESMO@OncoAlert proud to be part of it. @CHUdeToulouse#ESMO26
ESMO26: Adding nivolumab to perioperative chemo shows no significant benefit in muscle invasive bladder cancer. Watch Prof Andrea Necchi discuss his study👉https://t.co/YJfSULrHC5 @AndreaNecchi@MyUniSR#ESMO26#BladderCancer#OncologyResearch